ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: ...
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...
Company Engaging with U.S. and EU Regulatory Authorities to Determine the Optimal Global Pivotal Phase 3 Program for ANX007 The EMA’s PRIME designation provides early and proactive support to ...
BRISBANE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with ...
Company to hold investor conference call on Monday, July 31, 2023, at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., July 30, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc., a clinical-stage biopharmaceutical ...
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Please provide your email address to receive an email when new articles are posted on . Multimodal imaging and AI are both beneficial for managing patients with geographic atrophy. Cell therapies and ...
Company Engaging with U.S. and EU Regulatory Authorities to Determine the Optimal Global Pivotal Phase 3 Program for ANX007 BRISBANE, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results